Business
Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR
-- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":"\n-- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis --\n\n\n-- Magenta exercises option with Heidelberg Pharma for antibody-drug conjugates using an amanitin payload and targeting CD45 --\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nMagenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported new data showing successful immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. These results were presented yesterday at the American College of Rheumatology (ACR) Annual Meeting in Atlanta, Ga.\n\n\n“Millions of patients worldwide live with debilitating autoimmune diseases, with no options for curative therapy,” said John Davis, M.D, M.P.H., Chief Medical Officer, Magenta. “Magenta is developing targeted medicines such as CD45-ADC to enable more patients with autoimmune diseases to undergo a one-time, curative immune reset. The data presented at ACR provide important proof of concept for our immune reset platform across a broad range of diseases, including multiple sclerosis and systemic sclerosis. We expect to declare a development candidate and progress this medicine into IND-enabling studies next year as we work to allow more patients to live their lives without autoimmune disease.”\n\n\nCurrent standard treatment for patients with multiple sclerosis involves years of chronic dosing of medications that do not halt the progression of the disease. For patients with systemic sclerosis, a potentially fatal disease, there are no approved therapies. Immune reset through stem cell transplant has demonstrated durable remissions in thousands of patients with autoimmune diseases such as multiple sclerosis and systemic sclerosis, and it is recommended by the European League Against Rheumatism (EULAR) in treatment guidelines for systemic sclerosis. The immune reset process involves two main steps: removing the disease-causing cells and replacing them with healthy cells to rebuild the immune system to a healthy state.\n\n\nMagenta is the only company developing targeted antibody-drug conjugates designed to precisely remove the disease-causing cells in the body without the need for ch...